399 related articles for article (PubMed ID: 35256940)
1. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
2. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
[TBL] [Abstract][Full Text] [Related]
4. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
Zou P; Chen Z; He Q; Zhuo Y
Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
Wang Z; Kang W; Li O; Qi F; Wang J; You Y; He P; Suo Z; Zheng Y; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):694-707. PubMed ID: 33777676
[TBL] [Abstract][Full Text] [Related]
7. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells synergistically defend against CD8
Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1.
Dillen A; Bui I; Jung M; Agioti S; Zaravinos A; Bonavida B
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539569
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
Dudzinski SO; Cameron BD; Wang J; Rathmell JC; Giorgio TD; Kirschner AN
J Immunother Cancer; 2019 Aug; 7(1):218. PubMed ID: 31412954
[TBL] [Abstract][Full Text] [Related]
11. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
12. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
15. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
[TBL] [Abstract][Full Text] [Related]
16. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract][Full Text] [Related]
17. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
18. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
20. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
